{"title":"Shyamali Dharmage: mapping lung health trajectories across the life course","authors":"Tony Kirby","doi":"10.1016/s2213-2600(25)00198-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00198-5","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"46 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144488357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The importance of using appropriate reference ranges in spirometry","authors":"Peter Burney, Andre Amaral, Seif Shaheen","doi":"10.1016/s2213-2600(25)00191-2","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00191-2","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"46 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144479198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity","authors":"Ka Man Fong, Shek Yin Au, George Wing Yiu Ng","doi":"10.1016/s2213-2600(25)00161-4","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00161-4","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"31 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144479196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David R Spigel, Virginie Westeel, Ian C Anderson, Laurent Greillier, Florian Guisier, Olivier Bylicki, Firas B Badin, Gaelle Rousseau-Bussac, Clotilde Deldycke, Frank Griesinger, Adam Bograd, Wangjian Zhong, Jacques Le Treut, Sylvie Van Hulst, David R Gandara, Martin Reck, Petra Hoffknecht, Matthew A Gubens, John Crowley, Heiko von der Leyen, Maéva Zysman
{"title":"Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial","authors":"David R Spigel, Virginie Westeel, Ian C Anderson, Laurent Greillier, Florian Guisier, Olivier Bylicki, Firas B Badin, Gaelle Rousseau-Bussac, Clotilde Deldycke, Frank Griesinger, Adam Bograd, Wangjian Zhong, Jacques Le Treut, Sylvie Van Hulst, David R Gandara, Martin Reck, Petra Hoffknecht, Matthew A Gubens, John Crowley, Heiko von der Leyen, Maéva Zysman","doi":"10.1016/s2213-2600(25)00213-9","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00213-9","url":null,"abstract":"<h3>Background</h3>Survival for non-small-cell lung cancer (NSCLC) remains unacceptably low, even in stage IA–IIA. Current guidelines recommend adjuvant treatment for patients considered to be at high risk in stages IB and IIA, but suggest criteria that have not been validated to predict benefit. A previously validated, CLIA-certified 14-gene expression profile has identified patients with high-risk non-squamous NSCLC tumours in stages IA–IIA who benefitted from adjuvant chemotherapy in a non-randomised prospective study. In this prespecified interim analysis, we aimed to assess the efficacy and safety of platinum-based adjuvant chemotherapy in patients with stage IA–IIA molecular high-risk non-squamous NSCLC in a randomised trial.<h3>Methods</h3>AIM-HIGH, a randomised, phase 3 trial, was done at 45 centres in France, Germany, and the USA. Patients aged 18 years or older with stage IA–IIA non-squamous NSCLC, an adequate tumour sample, and an Eastern Cooperative Oncology Group performance status of 0–1 underwent risk stratification with the 14-gene assay. Patients with a molecular high risk, defined as those receiving a high-risk or an intermediate-risk score, were randomly assigned (1:1) to four cycles of platinum-based adjuvant chemotherapy (using local institutional standard of care regimens) or observation. Randomisation was stratified according to age, sex, and tumour size of 4 cm or more. The primary outcomes for the study and for this prespecified interim analysis were 48-month and 24-month disease-free survival, respectively, in the modified intention-to-treat (mITT) population, which was defined as randomly assigned patients who continued to meet eligibility criteria either at chemotherapy initiation or at random assignment to observation; an early interim analysis was prespecified to detect a large difference between groups. This trial is registered at <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT01817192</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and is closed to enrolment.<h3>Findings</h3>Between Sept 11, 2020, and Feb 7, 2025, 449 patients were enrolled and underwent risk stratification. 236 patients with molecular high risk were randomly assigned to chemotherapy (n=124) or observation (n=112). At the time of the prespecified interim analysis, 87 patients were evaluable in the mITT population (47 [54%] males and 40 [46%] females; median age 63 years [IQR 52–74]) in the chemotherapy group and 107 (58 [54%] males and 49 [46%] females; 66 years [56–76]) in the observation group. 48 (55%) patients in the chemotherapy group and 58 (54%) patients in the observatio","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"235 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144479187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to Lancet Respir Med 2024; 12: 714–27","authors":"","doi":"10.1016/s2213-2600(25)00235-8","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00235-8","url":null,"abstract":"<em>Meslé MMI, Brown J, Mook P, et al. Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study.</em> Lancet Respir Med <em>2024; <strong>12:</strong> 714–27</em>—In this Article, changes have been made in the Summary (Findings section and first sentence in the Interpretation section), Research in context panel (second-to-last sentence of the Added value of this study section and last sentence of the Implications of all the available evidence section), Methods (second sentence of first paragraph and the fourth paragraph in the Data analysis section), Results (paragraphs five and seven), figure 2 heading, and Discussion (paragraph five) to clarify the definition of the boosters doses and the authors' interpretation of their differential role in saving lives. These corrections were made June 23, 2025.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"12 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144371079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Toxic chlorine gas cloud in Vilanova: lessons to learn","authors":"Jordi Rello, Joan B Soriano","doi":"10.1016/s2213-2600(25)00196-1","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00196-1","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"30 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}